← Eichor
Study identifier: NCT06889844 Synced from ClinicalTrials.gov · July 29, 2026
● Recruiting

Observational Cross-reactivity Study for Colorectal Cancer Diagnosis

Condition: Colorectal Cancer  ·  Sponsor: ADVANCED MARKER DISCOVERY S.L.

PhaseN/A
Planned participants250
Who can joinAll sexes, 18 Years to no upper limit
Healthy volunteersNo

About this study

The objective of this observational study is to evaluate the false positive rate of the blood test based on molecular biomarkers and risk factors. A total of 250 patients diagnosed with various cancers and gastrointestinal diseases will be enrolled. The main question to be answered is Does the blood test have a low false positive rate in the main study population? Participants will donate a blood sample as part of their regular medical care for cancer diagnosis and give the consent to know their clinical risk factors.

This description comes directly from the study's public registry record.

Talk to the study team

Marta Jimenez  ·  +34637899149  ·  mjimenez@amadix.com

Always discuss trial participation with your own doctor first.

Locations (5)

Hospitales HM de MalagaMálaga, Andalusia, SpainRecruiting
Hospital Centro Médico AsturiasOviedo, Cantabria, SpainRecruiting
Hospital Universitario de OurenseOurense, Galicia, SpainRecruiting
Hospital Universitario HM SanchinarroMadrid, Madrid, SpainRecruiting
MD Anderson Cancer CentreMadrid, Madrid, SpainActive Not Recruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT06889844